BLeeding Events and Maintenance DoSe of PraSugrel

Launched by DAVID ANTONIUCCI · Feb 12, 2013

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • all ACS patients treated with PCI (percutaneous coronary intervention) and dual antiplatelet therapy (DAPT: aspirin plus prasugrel).
• • Informed written consent
• Exclusion Criteria:
• • Age \< 18 years
• • Active bleeding; bleeding diathesis; coagulopathy
• • History of gastrointestinal or genitourinary bleeding \<2 months
• • Major surgery in the last 6 weeks
• • History of intracranial bleeding or structural abnormalities
• • Suspected aortic dissection
• • Any previous TIA (transient ischemic attack)/stroke
• • Administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or fondaparinux .
• • Known relevant hematological deviations: Hb \<10 g/dl, Thrombocytopenia. \<100x10\^9/l
• • Use of coumadin derivatives within the last 7 days
• • Chronic therapy with prasugrel or ticagrelor
• • Known malignancies or other comorbid conditions with life expectancy \<1 year
• • Known severe liver disease, severe renal failure
• • Known allergy to the study medications
• • Pregnancy